Gland Pharma (BOM:543245) Cash-to-Debt : N/A (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Gland Pharma's cash to debt ratio for the quarter that ended in Dec. 2024 was N/A.

The historical rank and industry rank for Gland Pharma's Cash-to-Debt or its related term are showing as below:

BOM:543245' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.21 Med: 236.83 Max: 845.01
Current: 8.97

During the past 7 years, Gland Pharma's highest Cash to Debt Ratio was 845.01. The lowest was 5.21. And the median was 236.83.

BOM:543245's Cash-to-Debt is ranked better than
74.98% of 1007 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs BOM:543245: 8.97

Gland Pharma Cash-to-Debt Historical Data

The historical data trend for Gland Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Gland Pharma Cash-to-Debt Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

218.30

489.79

679.26

845.01

5.21

Gland Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															N/A	5.21	N/A	8.97	N/A

Competitive Comparison of Gland Pharma's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gland Pharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Gland Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Gland Pharma's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19387.5	/	(2309.47	+	1412.19)
	=	5.21

Gland Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Gland Pharma (BOM:543245) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Gland Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (BOM:543245) » Definitions » Cash-to-Debt

Traded in Other Exchanges

GLAND:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma Headlines

No Headlines